As a second-generation tyrosine kinase inhibitor (TKI), dasatinib which is 325-fold more potent against inhibition of BCR-ABL has shown advantages in treating newly diagnosed chronic phase chronic myeloid leukemia (CP CML) compared to imatinib. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.